Autonomic dysfunction in Parkinson's disease /

Detalles Bibliográficos
Clasificación:Libro Electrónico
Otros Autores: Falup-Pecurariu, Cristian
Formato: Electrónico eBook
Idioma:Inglés
Publicado: Cambridge, MA : Academic Press, 2021.
Colección:International review of movement disorders ; v. 1
Temas:
Parkinson's disease.
Dysautonomia.
Autonomic Nervous System Diseases
Maladie de Parkinson.
Dysautonomie.
Dysautonomia
Parkinson's disease
Acceso en línea:Texto completo
Tabla de Contenidos:
  • Intro
  • Autonomic Dysfunction in Parkinson�s Disease
  • Copyright
  • Contents
  • Contributors
  • Preface
  • Chapter One: Autonomic nervous system-Anatomy, physiology, biochemistry
  • 1. Anatomy of the autonomic nervous system (ANS)
  • 1.1. Central autonomic network
  • 1.2. Peripheral autonomic nervous system
  • 1.3. Sympathetic system
  • 1.4. Parasympathetic system
  • 2. Physiology and biochemistry of the autonomic nervous system
  • 2.1. Sympathetic system
  • 2.2. Parasympathetic system
  • 2.3. The fundamentals of ANS function
  • 2.4. The sympathetic and parasympathetic interaction
  • 3. Autonomic control of selected organ systems
  • 3.1. Cardiovascular autonomic control
  • 3.2. Autonomic control of bladder
  • 3.3. Gastrointestinal autonomic control
  • 3.4. Clinical implications and conclusion
  • References
  • Chapter Two: General approach to patients with autonomic dysfunction in Parkinson�s disease
  • 1. Introduction
  • 2. Epidemiology
  • 3. Pathophysiology
  • 3.1. Primary autonomic dysfunction in Parkinson�s disease
  • 3.2. Secondary autonomic dysfunction in Parkinson�s disease
  • 4. Clinical expression
  • 5. Diagnosis
  • 5.1. Validated scales and questionnaires
  • 5.2. Function tests
  • 6. Treatment
  • 7. Prognosis
  • 8. Conclusion
  • Acknowledgments
  • References
  • Chapter Three: Rating scales for dysautonomia in Parkinson�s disease
  • 1. Introduction
  • 2. Method
  • 3. Scales
  • 4. General assessment scales
  • 4.1. Non-motor symptoms questionnaire
  • 4.1.1. Scale description
  • 4.1.2. Properties of the NMS-quest
  • 4.1.2.1. Sensitivity and specificity
  • 4.1.2.2. Construct validity
  • 4.1.2.3. Reliability
  • 4.1.2.4. Acceptability
  • 4.1.2.5. Strengths and weaknesses
  • 4.1.2.6. Conclusions
  • 4.2. The non-motor symptoms scale (NMSS)
  • 4.2.1. Scale description
  • 4.2.2. Properties of the questionnaire
  • 4.2.2.1. Validity.
  • 4.2.2.2. Reliability
  • 4.2.2.3. Acceptability
  • 4.2.2.4. Strengths and weaknesses
  • 4.2.3. Conclusions
  • 4.3. COMPASS
  • 4.3.1. Scale description
  • 4.3.2. Properties of the questionnaire
  • 4.3.2.1. Content validity
  • 4.3.2.2. Construct validity
  • 4.3.2.3. Strengths and weaknesses
  • 4.3.2.4. Conclusion
  • 4.4. COMPASS-31
  • 4.4.1. Scale description
  • 4.4.2. Properties of the questionnaire
  • 4.4.2.1. Content validity
  • 4.4.2.2. Construct validity
  • 4.4.2.3. Internal consistency
  • 4.4.2.4. Strengths and weaknesses
  • 4.4.2.5. Conclusion
  • 4.5. MDS-unified Parkinson�s disease rating scale (MDS-UPDRS)
  • 4.5.1. Scale description
  • 4.5.1.1. Strengths and weaknesses
  • 4.5.1.2. Conclusion
  • 4.6. The scale for outcomes in Parkinson�s disease-autonomic (SCOPA-AUT)
  • 4.6.1. Scale description
  • 4.6.2. Properties of the questionnaire
  • 4.6.2.1. Content validity
  • 4.6.2.2. Construct validity
  • 4.6.2.3. Reliability
  • 4.6.2.4. Acceptability
  • 4.6.2.5. Strengths and weaknesses
  • 4.6.2.6. Conclusion
  • 5. Dysautonomia rating scales
  • 5.1. Gastrointestinal dysfunction
  • 5.2. MDS-UPDRS
  • 5.3. COMPASS and COMPASS 31
  • 5.4. The non-motor symptoms questionnaire (NMS quest)
  • 5.4.1. Strengths and weaknesses
  • 5.5. The non-motor symptoms scale (NMSS)
  • 5.5.1. Strengths and weaknesses
  • 5.6. SCOPA-AUT
  • 5.6.1. Strengths and weaknesses
  • 5.6.2. Conclusion
  • 6. Symptom specific scales
  • 6.1. Dysphagia
  • 6.2. Swallowing disturbance questionnaire (SDQ)
  • 6.2.1. Clinimetric properties
  • 6.2.2. Strengths
  • 6.2.3. Conclusions
  • 6.3. Dysphagia-specific quality of life (SWAL-QOL)
  • 6.3.1. Clinimetric properties
  • 6.3.1.1. Internal consistency
  • 6.3.1.2. Construct validity
  • 6.3.2. Acceptability
  • 6.3.3. Strengths
  • 6.3.4. Conclusions
  • 6.4. The Munich dysphagia test for Parkinson�s disease (MDT-PD)
  • 6.4.1. Clinimetric properties.
  • 6.4.1.1. Internal consistency
  • 6.4.1.2. Diagnostic validity and cross-validity
  • 6.4.1.3. Construct validity
  • 6.4.1.4. Strengths
  • 6.4.1.5. Limits
  • 6.4.1.6. Conclusions
  • 6.5. The Radbout oral motor inventory for Parkinson�s disease (ROMP)
  • 6.5.1. Clinimetric properties
  • 6.5.1.1. Reliability and reproductibility
  • 6.5.1.2. Acceptability
  • 6.5.1.3. Construct validity
  • 6.5.1.4. Conclusion
  • 6.5.2. Sialorrhea
  • 6.6. Sialorrhea clinical scale for PD (SCS-PD)
  • 6.6.1. Clinimetric properties
  • 6.6.1.1. Reliability
  • 6.6.1.2. Construct validity
  • 6.6.1.3. Acceptability
  • 6.6.1.4. Sensitivity and specificity
  • 6.6.1.5. Strengths
  • 6.6.1.6. Limits
  • 6.6.1.7. Conclusion
  • 6.7. Drooling rating scale (DRS)
  • 6.7.1. Clinimetric properties
  • 6.7.1.1. Strengths
  • 6.7.1.2. Limits
  • 6.7.1.3. Conclusion
  • 6.8. Drooling severity and frequency scale (DSFS)
  • 6.8.1. Clinimetric properties
  • 6.8.1.1. Strengths
  • 6.8.1.2. Limits
  • 6.8.1.3. Conclusion
  • 6.9. The Radbout oral motor inventory for Parkinson�s disease (ROMP)
  • 6.9.1. Clinimetric properties
  • 6.9.1.1. Reliability and reproductibility
  • 6.9.1.2. Acceptability
  • 6.9.1.3. Construct validity
  • 6.9.1.4. Conclusions
  • 6.9.2. Constipation
  • 6.9.3. ROME criteria
  • 6.9.4. Strengths
  • 6.9.5. Limits
  • 6.10. Other assessment tools
  • 6.11. Urinary dysfunction
  • 6.11.1. Introduction, definition and assessment of urinary dysfunction
  • 6.11.2. Scales and questionnaires
  • 6.12. SCOPA AUT
  • 6.13. NMS-QUEST
  • 6.14. NMS-SCALE
  • 6.15. COMPASS. COMPASS 31
  • 6.16. MDS-UPDRS
  • 6.17. International consultation on incontinence questionnaire (ICIQ)
  • 6.18. Clinimetric properties
  • 6.18.1. Content validity
  • 6.18.2. Construct validity
  • 6.18.3. Convergent validity
  • 6.18.4. Internal consistency
  • 6.18.5. Sensitivity
  • 6.18.6. Conclusion.
  • 6.19. International consultation on incontinence questionnaire-male LUTS (ICIQ-MLUTS)
  • 6.19.1. Description
  • 6.19.2. Clinimetric properties
  • 6.19.2.1. Internal consistency
  • 6.19.2.2. Test-retest reliability
  • 6.19.2.3. Criterion validity
  • 6.19.2.4. Conclusion
  • 6.20. Overactive bladder questionnaire (OABq)/OABq short form/eight-item OABq score/OAB symptom score
  • 6.20.1. Description
  • 6.20.2. Clinimetric properties
  • 6.20.2.1. Test-retest reliability
  • 6.20.2.2. Internal consistency
  • 6.20.2.3. Convergent validity
  • 6.20.2.4. Conclusion
  • 6.21. Danish prostatic symptom score
  • 6.21.1. Clinimetric properties
  • 6.21.1.1. Test-retest reliability
  • 6.21.1.2. Internal consistency
  • 6.21.1.3. Conclusion
  • 6.22. International prostate symptom score
  • 6.22.1. Clinimetric properties
  • 6.22.1.1. Internal consistency
  • 6.22.1.2. Test-retest reliability
  • 6.22.1.3. Sensitivity to change/responsiveness
  • 6.22.1.4. Conclusions
  • 6.23. The questionnaire on pelvic organ function
  • 6.23.1. Clinimetric properties
  • 7. Sexual dysfunction
  • 7.1. Introduction, definition and assessment of sexual dysfunction
  • 7.2. Scales and questionnaires
  • 7.3. Scales/questionnaires designed to assess non-motor symptoms
  • 7.4. SCOPA AUT
  • 7.4.1. Clinimetric properties
  • 7.5. NMS-QUEST
  • 7.5.1. Clinimetric properties
  • 7.6. NMS SCALE
  • 7.6.1. Clinimetric properties
  • 7.7. COMPASS 31
  • 7.8. MDS-UPDRS
  • 7.9. Scales focused on the sexual dysfunctions
  • 7.10. The Arizona sexual experience scale
  • 7.11. Clinimetric properties
  • 7.12. Quality of sexual life questionnaire
  • 7.12.1. Clinimetric properties
  • 7.13. Orthostatic hypotension
  • 7.13.1. Introduction, definition and assessment orthostatic hypotension
  • 7.13.2. Scales and questionnaires
  • 7.14. SCOPA-AUT
  • 7.14.1. Strengths and weaknesses
  • 7.14.2. Conclusion
  • 7.15. COMPASS.
  • 7.15.1. Strengths and weaknesses
  • 7.15.1.1. Conclusion
  • 7.16. COMPASS-31
  • 7.16.1. Strengths and weaknesses
  • 7.16.2. Conclusion
  • 7.17. The non-motor symptoms questionnaire (NMS quest)
  • 7.17.1. Strengths and weaknesses
  • 7.17.2. Conclusion
  • 7.18. The non-motor symptoms scale (NMSS)
  • 7.18.1. Strengths and weaknesses
  • 7.18.2. Conclusion
  • 7.19. MDS-UPDRS Part I
  • 7.19.1. Strengths and weaknesses
  • 7.19.2. Conclusion
  • 7.20. Orthostatic grading scale (OGS)
  • 7.20.1. Scale description
  • 7.20.2. Properties of the scale
  • 7.20.2.1. Content validity
  • 7.20.2.2. Internal consistency
  • 7.20.2.3. Construct validity
  • 7.20.2.4. Strengths and weaknesses
  • 7.20.2.5. Conclusion
  • 7.20.3. Conclusions
  • References
  • Chapter Four: Assessing autonomic dysfunction with functional imaging in Parkinson�s disease
  • 1. Introduction
  • 2. Imaging synaptic dysfunction and denervation of the autonomic nervous system
  • 2.1. Sympathetic denervation
  • 2.2. Parasympathetic denervation
  • 2.3. Brain-first versus body-first PD
  • 3. Imaging functional disturbances of the autonomic nervous system
  • 3.1. Gastrointestinal tract
  • 3.1.1. Oropharynx and esophagus
  • 3.1.2. Stomach
  • 3.1.3. Small intestine
  • 3.1.4. Colon
  • 3.1.5. Anorectal
  • 3.2. Urinary tract
  • 3.3. Thermoregulation of the skin
  • 4. Conclusion
  • References
  • Chapter Five: Cardiovascular autonomic failure in Parkinson�s disease
  • 1. Introduction
  • 2. Clinical presentation of cardiovascular autonomic failure in PD
  • 2.1. Orthostatic hypotension
  • 2.2. Post-prandial hypotension
  • 2.3. Exercise-induced hypotension
  • 2.4. Supine and nocturnal hypertension
  • 3. Diagnostic work-up of cardiovascular autonomic failure
  • 3.1. Diagnosis of neurogenic OH
  • 3.2. Diagnosis of supine and nocturnal hypertension.

Ejemplares similares